An experimental therapeutic compound developed by researchers at Michigan Medicine has successfully reversed a severe and often intractable form of fatty liver disease in animal studies. Rather than focusing exclusively on the liver itself, the treatment targets an unexpected and critical source of hepatic damage: the gastrointestinal tract.
The compound, identified as DT-109, operates through a multifaceted mechanism that involves reducing harmful bacterial populations within the gut, safeguarding the integrity of the intestinal lining, and preventing toxic inflammatory substances from migrating into the bloodstream and reaching the liver. According to findings published in The Journal of Clinical Investigation, this novel approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models, presenting a promising new pathway for treating a condition that has historically challenged clinicians and researchers alike.
MASH currently affects approximately 7% of the global population. It represents a particularly severe progression of fatty liver disease characterized by an excessive accumulation of fat within the liver, which subsequently triggers chronic inflammation and cellular injury. Over time, if left unchecked, the condition can advance to cirrhosis—a state marked by extensive, irreversible liver scarring—as well as primary liver cancer and terminal liver failure. Although therapeutic options for managing metabolic liver diseases have seen incremental improvements in recent years, effective and targeted treatments remain severely limited in clinical practice.
"We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression," said Dr. Eugene Chen, senior author of the study and the Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School. "This compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH."
How Harmful Gut Bacteria Can Trigger Liver Damage
Dr. Chen’s research laboratory had previously demonstrated that DT-109, a glycine-based tripeptide, possessed the capability to ameliorate MASH in animal studies. A tripeptide is a compact molecule constructed from three amino acids, which serve as the fundamental building blocks of proteins within biological systems. However, despite these earlier observations, the precise biological mechanisms through which the compound produced its protective effects remained unclear.
The latest research provides a comprehensive explanation, revealing how alterations in the composition of gut bacteria can initiate a destructive biochemical chain reaction that ultimately damages the liver, while simultaneously detailing how DT-109 can effectively interrupt that pathological process.
Before evaluating the direct therapeutic effects of the drug, the scientific team sought to confirm a primary driver of MASH pathogenesis: the excessive proliferation of Clostridium perfringens, a specialized bacterium known for producing high levels of ammonia within the intestinal environment. When local ammonia concentrations rise significantly, they exert a corrosive effect on the gut’s delicate protective inner lining.
Under normal physiological conditions, this robust intestinal barrier functions as a selective filter, preventing potentially harmful substances, toxins, and microbial byproducts from escaping the digestive tract and entering the systemic circulation. However, as this barrier becomes compromised and weakens, toxins and metabolic waste generated by intestinal microbes are granted free passage to travel directly to the liver via the portal circulation. Once these foreign elements arrive in the hepatic tissue, they provoke intense inflammation and aberrant immune system activation that rapidly accelerates liver tissue damage.
One critical component of this inflammatory cascade involves the hyperactivation of CD8+ T cells, specialized immune cells that under normal circumstances assist the body in eliminating infected or abnormal cells. When these immune cells become chronically overactive within the liver, they actively exacerbate the destructive inflammatory processes characteristic of MASH. These findings collectively help elucidate why a disease traditionally classified as a primary hepatic disorder is so profoundly influenced by physiological events transpiring elsewhere in the digestive apparatus.
Experimental Drug Repairs the Gut and Protects the Liver
Through a rigorous series of controlled experiments, the research team discovered that DT-109 disrupts this vicious biological cycle by normalizing the intestinal environment and reinforcing the structural integrity of the gut’s protective barrier.
In both murine models and nonhuman primates, administration of the compound successfully reduced population levels of Clostridium perfringens and lowered ammonia production within the intestines. These targeted biochemical changes helped fortify the intestinal lining, thereby restricting the translocation of harmful microbial substances into the broader circulatory system and mitigating their capacity to inflict injury upon the liver tissue.
The therapeutic outcomes were notably encouraging when observed in nonhuman primates, whose overall liver physiology, metabolic profiles, and gut microbial ecosystems bear a much closer resemblance to human biology than those of mice. In these higher-order animal models, treatment with DT-109 demonstrably decreased hepatic inflammation and reduced the overall clinical severity of MASH.
Taken together, these data demonstrate how intervening in pathological processes within the gut can yield profound downstream benefits within the liver, despite the drug exerting its primary pharmacological actions within the gastrointestinal tract itself.
"DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis," explained Dr. Jifeng Zhang, co-author of the study and a research professor of cardiovascular medicine at the U-M Medical School. "We also found that DT-109 primarily acts in the gastrointestinal tract, but its reach stretches much further."
The term "gut-liver axis" refers to the intimate anatomical and functional relationship connecting the digestive tract and the liver. Nutrients and other substances absorbed across the intestinal mucosa travel directly to the liver via the portal veinous system, rendering hepatic health acutely sensitive to fluctuations in gut microbiome composition and intestinal barrier function. By capitalizing on this physiological connection, DT-109 offers an innovative mechanism to counteract the fundamental drivers of liver inflammation rather than merely attempting to manage hepatic damage after it has already occurred.
Potential Benefits Beyond Fatty Liver Disease
Investigators believe that the compound’s intrinsic ability to protect and restore the intestinal barrier could render it broadly useful against a wider array of human pathologies characterized by chronic inflammation and metabolic dysfunction.
Previous investigations conducted by the research group established that DT-109 can significantly diminish the formation of atherosclerotic plaques and forestall vascular calcification in nonhuman primates. Atherosclerotic plaques consist of accumulated deposits of cholesterol, fat, and cellular waste products that line the interior walls of arteries, potentially restricting vital blood flow and elevating the overall risk of acute cardiovascular events. Vascular calcification, by contrast, occurs when mineralized calcium deposits accumulate within blood vessel walls, causing them to lose elasticity and stiffen, which further contributes to progressive cardiovascular disease.
These converging lines of evidence suggest that DT-109 could eventually hold significant therapeutic applications for both hepatological and cardiovascular conditions—an exceptionally relevant possibility given that metabolic disorders frequently manifest across multiple organ systems simultaneously.
Furthermore, the research team is actively exploring whether the compound might offer therapeutic benefits for individuals suffering from inflammatory bowel disease (IBD), a category of chronic inflammatory conditions of the digestive tract that includes Crohn’s disease and ulcerative colitis. Because structural and functional impairments of the intestinal barrier are hallmark features associated with several distinct gastrointestinal disorders, a therapeutic agent capable of reinforcing this barrier could theoretically provide benefits far beyond protecting the liver alone. Nonetheless, the researchers emphasize that dedicated, rigorous investigation will be required to establish whether DT-109 can be successfully adapted for these additional conditions.
A Promising Treatment That Still Needs Human Trials
Despite these highly encouraging preclinical findings, DT-109 remains strictly an experimental therapeutic agent. Its capacity to reverse MASH has been robustly documented in various animal models, but researchers have not yet formally proven whether the compound can safely and effectively replicate these clinical benefits in human patients.
The upcoming phase of research will focus on the continued evaluation of the compound with the ultimate objective of advancing it toward formal human clinical trials. Such studies will be indispensable for determining optimal dosing, long-term safety profiles, and genuine therapeutic efficacy in clinical populations.
"This study presents novel evidence about the pathogenesis of MASH and provides excitement about a therapeutic avenue to explore for a condition that remains difficult to treat," noted Dr. Elliot Tapper, Academic Director of Hepatology at Michigan Medicine. "What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health—of course we are excited about these developments."
This discovery underscores an important conceptual shift in contemporary medical science regarding how researchers approach complex metabolic and fatty liver diseases. By addressing aberrant gut microbiota and actively repairing the intestinal barrier, scientists may soon be capable of protecting vital internal organs using treatments that operate primarily outside the organ boundaries themselves.
If forthcoming human clinical trials successfully validate the therapeutic benefits observed in animal models, DT-109 could introduce an entirely new class of treatment options for patients suffering from severe fatty liver disease, while simultaneously addressing complex cardiovascular comorbidities.
Funding and Disclosures
Ying Zhao, Oren Rom, Jifeng Zhang, and Y. Eugene Chen are formally listed as coinventors on a patent application concerning tripeptides and their utility in the treatment of metabolic, cardiovascular, and inflammatory disorders.
Dr. Chen is also recognized as an inventor of DT-109 specifically. The University of Michigan holds the foundational patent rights for the compound and has successfully licensed the technology to Diapin Therapeutics. Both Dr. Chen and the University of Michigan maintain financial ownership interests in Diapin, the corporate entity that supplied the DT-109 compound utilized in the research and which is overseeing its continued commercial development.
The clinical protocols, associated amendments, and informed consent documentation for the related human studies received formal ethical approval from the Institutional Review Boards at all participating clinical sites. These participating institutions included the First Affiliated Hospital of Xi’an Jiaotong University (under approval number XJTU1AF2023LSK330), the Institutional Review Board of Jinan University (approval number 2016-017), and the University of Hong Kong/Hospital Authority Hong Kong West Cluster (approval number UW 20-700).
All experimental procedures involving nonhuman primates were conducted following review and formal approval by the Laboratory Animal Care Committee of Xi’an Jiaotong University (approval number 20191278) and the Institutional Animal Care and Use Committee of Spring Biological Technology Development Co., Ltd. (approval number 201901). All animal studies were performed in strict accordance with the ethical guidelines set forth in the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
